Ji Jie, Jin Dandan, Zhao Junpeng, Xie Xudong, Jiao Yujie, He Xuyang, Huang Yuxuan, Zhou Lirong, Xiao Mingbing, Cao Xiaolei
Department of Gastroenterology, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, Jiangsu, China.
Department of Gastroenterology, Affiliated Changshu Hospital of Nantong University, Changshu, Jiangsu, China.
Clin Transl Med. 2025 Jul;15(7):e70354. doi: 10.1002/ctm2.70354.
Pancreatic cancer (PC) is an extremely deadly type of cancer, and the 5-year survival rate remains less than 10%. The tumour microenvironment (TME) affects the occurrence, progression and treatment outcomes of PC. MicroRNAs (miRNAs) are essential to regulate PC TME. This review delves into the different roles of miRNAs in the PC TME, including exosome communication, angiogenesis, interactions with cancer-associated fibroblasts, the immunological and neuronal microenvironments and metabolic reprogramming. However, research on the complex regulatory networks and synergistic effects of miRNAs in the TME is still insufficient, and their clinical translation and application face challenges. This review summarised the activities of miRNAs in the PC TME, guiding future research and therapeutic strategies involving miRNAs in PC. Future studies should integrate advanced technologies to decode the spatiotemporal dynamics of miRNA regulation within the TME and develop optimised nanodelivery systems for stable and targeted miRNA delivery, advancing clinical applications in PC treatment.
胰腺癌(PC)是一种极其致命的癌症类型,其5年生存率仍低于10%。肿瘤微环境(TME)影响着胰腺癌的发生、发展和治疗结果。微小RNA(miRNA)对调节胰腺癌TME至关重要。本综述深入探讨了miRNA在胰腺癌TME中的不同作用,包括外泌体通讯、血管生成、与癌症相关成纤维细胞的相互作用、免疫和神经微环境以及代谢重编程。然而,关于miRNA在TME中的复杂调控网络和协同作用的研究仍然不足,其临床转化和应用面临挑战。本综述总结了miRNA在胰腺癌TME中的活性,为未来涉及miRNA的胰腺癌研究和治疗策略提供指导。未来的研究应整合先进技术,以解码TME内miRNA调控的时空动态,并开发优化的纳米递送系统,以实现稳定且靶向的miRNA递送,推动其在胰腺癌治疗中的临床应用。
Clin Transl Med. 2025-7
Cochrane Database Syst Rev. 2018-2-6
Front Cell Infect Microbiol. 2025-6-10
Graefes Arch Clin Exp Ophthalmol. 2025-1-6
J Hematol Oncol. 2025-3-28
Cancer Lett. 2025-2-1
ACS Pharmacol Transl Sci. 2024-8-7
Drug Resist Updat. 2024-11